Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.
Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group. Iwata H, et al. Among authors: kusama m. Breast Cancer. 2005;12(2):99-103. doi: 10.2325/jbcs.12.99. Breast Cancer. 2005. PMID: 15858439 Free article. Clinical Trial.
Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors.
Komoike Y, Akiyama F, Iino Y, Ikeda T, Tanaka-Akashi S, Ohsumi S, Kusama M, Sano M, Shin E, Suemasu K, Sonoo H, Taguchi T, Nishi T, Nishimura R, Haga S, Mise K, Kinoshita T, Murakami S, Yoshimoto M, Tsukuma H, Inaji H. Komoike Y, et al. Among authors: kusama m. Breast Cancer. 2005;12(2):104-11. doi: 10.2325/jbcs.12.104. Breast Cancer. 2005. PMID: 15858440 Free article.
Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.
Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S, Kusama M, Sano M, Shin E, Suemasu K, Sonoo H, Taguchi T, Nishi T, Nishimura R, Haga S, Mise K, Kinoshita T, Murakami S, Yoshimoto M, Tsukuma H, Inaji H. Komoike Y, et al. Among authors: kusama m. Cancer. 2006 Jan 1;106(1):35-41. doi: 10.1002/cncr.21551. Cancer. 2006. PMID: 16333848 Free article.
Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.
Anan K, Mitsuyama S, Yanagita Y, Kimura M, Doihara H, Komaki K, Kusama M, Ikeda T. Anan K, et al. Among authors: kusama m. Breast Cancer Res Treat. 2011 Aug;128(3):775-81. doi: 10.1007/s10549-011-1608-x. Epub 2011 Jun 3. Breast Cancer Res Treat. 2011. PMID: 21638048 Clinical Trial.
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
Shien T, Doihara H, Sato N, Anan K, Komaki K, Miyauchi K, Yanagita Y, Fujisawa T, Mitsuyama S, Kanbayashi C, Kusama M, Kimura M, Jinno H, Sano M, Ikeda T. Shien T, et al. Among authors: kusama m. Cancer Chemother Pharmacol. 2018 Feb;81(2):269-275. doi: 10.1007/s00280-017-3491-6. Epub 2017 Dec 1. Cancer Chemother Pharmacol. 2018. PMID: 29196963 Free PMC article. Clinical Trial.
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer.
Ohnoa S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Shin E, Kaise H, Kurozumi M, Tsuda H, Akiyama F. Ohnoa S, et al. Among authors: kusama m. Biomed Pharmacother. 2005 Oct;59 Suppl 2:S323-4. doi: 10.1016/s0753-3322(05)80063-0. Biomed Pharmacother. 2005. PMID: 16507401
161 results